Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.76 |
| ▸ | MEN1 | O00255 | 4/20 | 0.76 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | F13A1 | P00488 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | TGM1 | P22735 | 1/20 | 0.52 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15267699 | 0.91 | KMT2A (0.60) | KMT2AMEN1HPGDNPC1RAB9A | |
| SCHEMBL5663326 | 0.89 | KMT2A (0.61) | KMT2AMEN1HPGDNPC1RAB9A | |
| SCHEMBL16140981 | 0.86 | KMT2A (1.00) | KMT2AMEN1HPGDNPC1RAB9A | |
| SCHEMBL23088339 | 0.86 | KMT2A (0.74) | KMT2AMEN1HPGDNPC1RAB9A | |
| SCHEMBL22397597 | 0.83 | KMT2A (0.70) | KMT2AMEN1HPGDNPC1RAB9A | |
| SCHEMBL7888049 | 0.83 | CYP1A1 (0.60) | KMT2AMEN1HPGDNPC1RAB9A | |
| SCHEMBL5271791 | 0.83 | KMT2A (0.76) | KMT2AMEN1HPGDNPC1RAB9A | |
| SCHEMBL6932064 | 0.81 | MAPT (0.59) | KMT2AMEN1HPGDNPC1RAB9A | |
| SCHEMBL11638641 | 0.81 | SMN1; SMN2 (0.59) | KMT2AMEN1HPGDNPC1RAB9A | |
| SCHEMBL7445670 | 0.81 | KMT2A (0.73) | KMT2AMEN1HPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951602-B2 | Mass defect labeling and methods of use thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-05-31 | — | — | US | claimed |
| US-20090061523-A1 | MASS DEFECT LABELING AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-05 | — | — | US | claimed |
| US-20240034727-A1 | IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 | Stingray Therapeutics, Inc. | 2024-02-01 | — | — | US | disclosed |
| CN-116963733-A | Imidazole compounds as ENPP1 inhibitors | 斯汀格瑞治疗股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-4255425-A1 | IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 | Stingray Therapeutics, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-110790724-B | Selective carbonic anhydrase inhibitor and synthesis method and application thereof | 中山大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-110734417-B | 2-butenolide acetamide compound and preparation method and application thereof | 南开大学 | 2022-09-30 | — | — | CN | disclosed |
| WO-2022119928-A1 | IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 | Stingray Therapeutics, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022119928-A1 | IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 | Stingray Therapeutics, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| CN-110790724-A | Selective carbonic anhydrase inhibitor and synthesis method and application thereof | 中山大学 | 2020-02-14 | — | — | CN | disclosed |
| CN-110734417-A | 2-butenolide acetamide compound and preparation method and application thereof | 南开大学 | 2020-01-31 | — | — | CN | disclosed |
| WO-2002092019-A2 | HALOGENATED ANTITUBERCULOSIS AGENTS | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020173548-A1 | HALOGENATED ANTITUBERCULOSIS AGENTS | SCIENCES IN PHILADELPHIA, UNIVERSITY OF | 2002-11-21 | — | — | US | disclosed |
| US-6482982-B1 | BACTERICIDES; MYCOBACTERIUM RESISTANCE | UNIVERSITY OF SCIENCES OF PHILADELPHIA | 2002-11-19 | — | — | US | disclosed |
| WO-2002090443-A1 | SYNTHESIS AND EVALUATION OF NEW CYANINE DYES AS MINOR GROOVE OF [POLY(DA-DT)]2 BINDERS | LIGHT UP TECHNOLOGIES AB (SE) | 2002-11-14 | — | — | WO | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| CN-1292697-A | Anti-viral compound | LILLY CO ELI (US) | 2001-04-25 | — | — | CN | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| US-4102924-A | REACTING ACYLAMINO-ARYLS WITH HALO-ARYLS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034727-A1 | IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 | ENPP1, PPP1R1B, PPM1B | KMT2A 2718/4885MEN1 231/4885HPGD 3519/4885 |
| US-20090061523-A1 | MASS DEFECT LABELING AND METHODS OF USE THEREOF | PTMS, SPPL2B, NPPA | KMT2A 4449/4885MEN1 654/4885HPGD 3828/4885 |
| US-20020173548-A1 | HALOGENATED ANTITUBERCULOSIS AGENTS | XDH, TST, QSOX1 | KMT2A 2746/4885MEN1 4691/4885HPGD 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.